摘要
目的:探讨格列喹酮联合阿托伐他汀治疗早期糖尿病肾病(diabetic kidney disease,DKD)的临床疗效。方法:选取早期DKD患者64例,以随机数字表法分为对照组和观察组,每组32例。对照组患者口服格列喹酮45~120 mg/d,观察组患者在对照组基础上联合口服阿托伐他汀10 mg/d,比较两组患者治疗前后血清肌酐(SCr)、24 h尿蛋白排泄率(24 h UAER)、糖化血红蛋白(HbA_1c)、总胆固醇(TC)及低密度脂蛋白胆固醇(LDL-C)水平。结果:治疗3个月后,两组患者的HbA_1c、24 h UAER水平均较治疗前明显降低,差异均有统计学意义(P<0.05);观察组患者的24 h UAER、TC及LDL-C水平明显低于对照组,差异均有统计学意义(P<0.05)。治疗6个月后,两组患者的HbA_1c、24 h UAER水平均较治疗前明显降低,差异均有统计学意义(P<0.05);观察组患者的SCr水平较治疗前明显降低,差异有统计学意义(P<0.05),而对照组的SCr水平与治疗前的差异无统计学意义(P>0.05);观察组的24 h UAER、SCr、TC及LDL-C水平明显低于本组治疗3个月时,且明显低于对照组,差异均有统计学意义(P<0.05)。结论:格列喹酮与阿托伐他汀联合应用更有利于早期DKD的改善,长期血脂控制、保护肾脏等作用更明显。
OBEJECTIVE： To probe into the efficacy of gliquidone combined with atorvastatin in treatment of early diabetic kidney disease（ DKD）. METHODS： 64 patients with early DKD were selected and divided into control group and observation group via random number table,with 32 cases in each. The control group was given 45-120 mg/d of gliquidone orally,while the observation group was given 10 mg/d of atorvastatin orally based on the control group,levels of serum creatinine（ SCr）,urinary albumin excretion rate in 24 h（ 24 h UAER）,glycosylated hemoglobin（ HbA_1c）,total cholesterol（ TC） and low density lipoprotein cholesterin（ LDL-C） of two groups were compared. RESULTS： After 3-month treatment,the HbA_1c and 24 h UAER levels of both groups had been significantly decreased,with statistically significant differences（ P〈0. 05）; the 24 h UAER,TC and LDL-C levels of observation group were significantly lower than those of the control group,with statistically significant differences（ P〈0. 05）. After 6-month treatment,the HbA_1c and 24 h UAER levels of both groups had been significantly decreased,with statistically significant differences（ P〈0. 05）; the Scr level of observation group was significantly lower than that of before treatment,with statistically significant differences（ P〈0. 05）,while there was no statistical significance in difference of SCr level in control group between before and after treatment（ P〈0. 05）; at 6 months after treatment,the 24 h UAER,SCr,TC and LDL-C levels of observation group were significantly lower than those of 3 months after treatment,and also significantly lower than those of the control group,with statistically significant differences（ P〈0. 05）. CONCLUSIONS： The combination of gliquidone and atorvastatin is more beneficial to the improvement of early DKD,which makes more significant differences in long-term blood lipid control and kidney protection.
作者
赵大坤
王婧
刘丽
俞群
ZHAO Dakun1 , WANG Jing2, LIU Li1 , YU Qun1(1. Dept. of Endocrine Oncology, Nanyuan Hospital of Fengtai, Beijing 100076, China; 2. Dept. of Cancer Center, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing 100050, Chin)
出处
《中国医院用药评价与分析》
2018年第5期580-582,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
国家自然科学基金(No.81000187)
